MINNEAPOLIS (June 17, 2016) — Mallinckrodt Pharmaceuticals (NYSE: MNK), a global specialty biopharmaceutical company, announced this week that it will purchase and donate more than 1 million Deterra® drug deactivation pouches to help prevent the abuse of prescription pain medications.
The Omnidegradable® pouches, made by Minneapolis-based Verde Technologies, use patented Molecular Adsorption Technology (MAT12®) to neutralize the active ingredients in opioid painkillers and other drugs in pill, liquid and transdermal patch forms. A proprietary activated carbon bonds to pharmaceutical compounds when water is added, rendering the drugs ineffective and safe for disposal in any setting – home, clinic or hospital.
“As a company focused on our patients and communities, Mallinckrodt has long been a strong advocate of addressing the complex issues of opioid misuse and abuse that cause so much harm to families,” said Mark Trudeau, Mallinckrodt President and Chief Executive Officer. “We share the concerns of parents around the country, and believe that providing patients with a safe, environmentally responsible way to dispose of unused medications is critical in this fight against prescription drug abuse.”
Mallinckrodt plans to distribute the pouches through collaboration with policymakers and community leaders who share its goal of building public awareness of the critical role of responsible drug disposal in the fight against prescription drug abuse. Previously, Mallinckrodt donated about 500,000 Deterra pouches to providers, patient groups and other stakeholders through partnerships with organizations such as CADCA, The Jed Foundation and ACT Missouri.
A national survey of U.S. adults who used opioids showed that nearly 6 out of 10 had or expect to have leftover opioids, according to findings published this month in the JAMA Internal Medicine journal. Nearly 68 percent of those who used prescription pain relievers non-medically in 2012-2013 got them from friends or relatives, according to the 2013 Substance Abuse and Mental Health Services Administration National Survey on Drug Use and Health.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
About Verde Technologies
Minneapolis-based Verde Technologies is committed to developing research-based, scientifically proven solutions to reduce drug abuse and misuse. The Deterra Drug Deactivation System is powered by patented MAT12 Molecular Adsorption Technology, which deactivates prescription drugs using proprietary activated carbon. The technology is highly effective in adsorbing and firmly binding pharmaceuticals, rendering them inactive and ineffective for misuse. For more information, visit www.DeterraSystem.com, follow @DeterraSystem on Twitter or like Deterra System on Facebook.